Pacific Edge Limited · NZX:PEB
Pacific Edge — Shareholder Meeting (August 2017)
22 slides from Pacific Edge's shareholder meeting presentation, Aug 24, 2017
Slide 1: Annual Meeting of Shareholders 24 August 2017
Annual Meeting of Shareholders 24 August 2017
Slide 2: Board of Directors
BOARD OF DIRECTORS Chris Gallaher Independent Director GOVERNANCE Chairman Board of Directors Experience in governance, finance, cancer research, biotechnology and life sciences, David Band Independent Director investment and business advisory. Subsidiary Board Directors Bryan Williams Independent D
Slide 3: Meeting Agenda
MEETING AGENDA • Presentations: • Address from the Chair, Chris Gallaher • Address from the Chief Executive Officer, David Darling • Shareholder Discussion • Resolutions as per Notice of Meeting: • Re-election of David Darling as a Director • Re-election of Bryan Williams as a Director • Authorise t
Slide 4: Targeting Large Scale Markets
TARGETING LARGE SCALE MARKETS Pacific Edge 2017 Presentation Slide 4
Slide 5: USA Revenue Recognition
USA REVENUE RECOGNITION • USA generates 90% of Pacific Edge’s revenue Pacific Edge provides test to patient covered by Medicare • Until now, has been dominated by tests run for CMS patients • Recovery of the revenue from these tests is largely controlled by the Pacific Edge billing and reimbursement
Slide 6: Commercial Traction
COMMERCIAL TRACTION Pacific Edge 2017 Presentation 6
Slide 7: Chief Executive Officer
CHIEF EXECUTIVE OFFICER David Darling Pacific Edge 2017 Presentation Slide 7
Slide 8: Our Purpose and Strategy
OUR PURPOSE AND STRATEGY Delivering Innovative Solutions for the Early Detection and Management of Cancer • Focus on haematuria and urothelial cancer; commercialising a suite of Cxbladder tests (one-stop-shop) • The United States is the world’s largest healthcare market and our primary focus. • Have
Slide 9: Haematuria and Urothelial Cancer
HAEMATURIA AND UROTHELIAL CANCER Haematuria is symptomatic of bladder cancer • 7 million people in the USA present with haematuria every year • Clinical guidelines require they be worked up with expensive and invasive procedures • Following treatment patients are required to be monitored every 4-6 m
Slide 10: Cxbladder Spans the Clinical Pathway
CXBLADDER SPANS THE CLINICAL PATHWAY A World First UROTHELIAL CANCER: Non Invasive, Accurate, Fast, Low Cost, High PRIMARY HEALTHCARE (General Practitioner) 80% 20% Utility Cxbladder Triage Frontline tool for use by In-Market physicians in the early 1.5 MILLION PATIENTS WITH 2015/16 evaluation of ha
Slide 11: FY17 Milestones
FY17 MILESTONES Significant Progress Achieved Joint analysis of Kaiser Permanente study completed with positive and compelling results Approved provider to Official US launch of TRICARE Cxbladder Monitor APRIL MAY JUNE JULY AUG SEPT OCT NOV DEC JAN FEB MAR Cxbladder Monitor MTANZ Award Insurance cov
Slide 12: FY17 Financials (for 12 months to 31 March 2017)
FY17 FINANCIALS (FOR 12 MONTHS TO 31 MARCH 2017) 62% Uplift in Product Sales OPERATING REVENUE Positive growth in product sales from new and existing 10 In the past four years, operating revenue has grown from customers, particularly in North America. $150,000 to $8.1 million 8 62% increase 6 in ope
Slide 13: Transformational Customers
TRANSFORMATIONAL CUSTOMERS Veterans Administration and TRICARE VETERANS ADMINISTRATION KAISER PERMANENTE COMPLETED √ Signed Federal Supply Schedule Agreement COMPLETED √ Completion of large scale User Programme in first half (Feb 2016) and negotiated contract price for FY17 and positive analysis wit
Slide 14: Other Markets
OTHER MARKETS New Zealand, Australia, South East Asia AUSTRALIA • Tolmar Australia - dedicated urology sales executives leveraging their existing networks • Targeting large hospitals as well as individual urologists • Three Cxbladder products now available in market NEW ZEALAND • Agreements with sev
Slide 15: Revenue Outlook and Drivers
REVENUE OUTLOOK AND DRIVERS FY18 Revenue Uplift Expected In Line With Annual Trends • United States remains the primary focus MARKETS • New Zealand: Continue to encourage uptake by DHBs • Australia: Conversion of User Programmes and greater sales coverage • Singapore: Grow User Programme base and in
Slide 16: Priorities for FY18
PRIORITIES FOR FY18 MARKETS CUSTOMERS • United States remains the primary focus • Bring Kaiser Permanente on board as commercial customer • New Zealand: Continue to encourage uptake by DHBs • Build commercial relationships with targeted large scale VA • Australia: Conversion of User Programmes with
Slide 17: Shareholder Discussion
SHAREHOLDER DISCUSSION Pacific Edge 2017 Presentation Slide 17
Slide 18: Resolutions
RESOLUTIONS RESOLUTION 1: That David Darling, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company RESOLUTION 2: That Bryan Williams, who retires by rotation and is eligible for re-election, be re-elected as a Director of the Company RESOLUTION 3: That
Slide 19: Proxies and Voting
PROXIES AND VOTING We have received the following valid votes and proxies: PROXIES AND POSTAL VOTES FOR AGAINST DISCRETIONARY VALID % OF TOTAL VOTES/PROXIES ISSUED RECEIVED CAPITAL Re-election of David 151,751,045 23,180,250 1,393,236 176,324,531 44.11% Darling (Resolution 1) 86.06% 13.15% 0.79% Re-
Slide 20: Other Business
OTHER BUSINESS Pacific Edge 2017 Presentation Slide 20
Slide 21: Close of the Meeting
CLOSE OF THE MEETING Presentations are available at www.pacificedgedx.com David Darling Chief Executive Officer Pacific Edge Limited www.pacificedge.co.nz Tel: +64 3 479 5802 Mobile: +64 21 797981 www.cxbladder.com Email: david.darling@pelnz.com www.pacificedgedx.com Pacific Edge 2017 Presentation
Slide 22: Disclaimer
DISCLAIMER Information The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of Pacific Edge Limited . The information in this presen